Explore

Companies

Drugs

/

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Other/Chemoradiation

Chemoradiation

5

Pipeline Programs↗

5

Active Trials↗

0

Companies Involved↗

Chemoradiation is an early-stage landscape with 5 programs across 0 companies.

Intelligence

Pipeline Metrics

Competitive Density

32/100

Pipeline Velocity

6/100

Mech. Concentration

100/100

Completion Rate

72/100

Attrition Rate

14/100

Pipeline

Programs by Phase

Preclinical1

Cancer Immunotherapy

Massachusetts General Hospital

Phase 1

No programs

Phase 24

Concurrent Cisplatin Chemotherapy

Chongqing University Cancer Hospital

Camrelizumab

Sun Yat-sen University

S1,

Chinese Academy of Medical Sciences

Iparomlimab

Tianjin Medical University Cancer Institute and Hospital

Phase 3

No programs

Approved

No programs

Analysis

Modality Breakdown

4programs

Small molecule250%

Monoclonal antibody250%

Modality classified for 100% of 5 pipeline programs.

Analysis

Trial Status

28

clinical trials

Completed13 · 46%

Unknown status5 · 18%

Recruiting4 · 14%

Terminated2 · 7%

Withdrawn2 · 7%

Not yet recruiting1 · 4%

Other1 · 4%

Clinical Trials

Trial Activity

28 trials

Tislelizumab Plus Concurrent Chemoradiation in Older With ESCC

Recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT06061146·136 enrolled

Chemoradiation Plus Iparomlimab Consolidation in Older With ESCC

Recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT07038629·52 enrolled

The Efficacy of Induction and Adjuvant Camrelizumab Combined With Chemoradiation for LA-HNSCC

Recruiting·—·Phase 2·NCT05213884·30 enrolled

Chemoradiation and Consolidation Chemotherapy With or Without Oxaliplatin for Distal Rectal Cancer and Watch and Wait

Recruiting·—·N/A·NCT05000697·216 enrolled

Sintilimab-Nimotuzumab Induction Followed by Chemoradiation-Nimotuzumab in LA-HNSCC: Single-Arm Phase II

Not yet recruiting·FFujian Cancer Hospital·Phase 2·NCT07310771·23 enrolled

Neo-adjuvant Chemoradiation With Oxaliplatin/5-FU in Rectal Cancer

Completed·—·Phase 2·NCT00831181·27 enrolled

Neoadjuvant Chemoradiation With RHUMAB VEGF (Avastin) for Rectal Cancer

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00113230·25 enrolled

Chemoradiation or Brachytherapy for Rectal Cancer

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT02017704·9 enrolled

Metformin With Neoadjuvant Chemoradiation to Improve Pathologic Responses in Rectal Cancer

Completed·SSunnybrook Health Sciences Centre·Phase 2·NCT03053544·15 enrolled

A Pilot Study to Evaluate PBR PET in Brain Tumor Patients Treated With Chemoradiation or Immunotherapy

Completed·MMassachusetts General Hospital·N/A·NCT02431572·11 enrolled

Oxaliplatin and 5-FU Based Preoperative Chemoradiation

Completed·OOslo University Hospital·Phase 2·NCT00278694·109 enrolled

Consolidation Pembrolizumab Following Chemoradiation in Patients With Inoperable/Unresectable Stage III NSCLC

Completed·—·Phase 2·NCT02343952·93 enrolled

Preoperative Chemoradiation With VMAT-SIB in Rectal Cancer

Completed·IIRCCS Azienda Ospedaliero-Universitaria di Bologna·Phase 2·NCT02745639·18 enrolled

PReoperative Chemoradiation (Paclitaxel-carboplatin or FOLFOX) for Resectable Esophageal and Junctional Cancer

Completed·CCentre Oscar Lambret·Phase 2·NCT02359968·106 enrolled

Preoperative Chemoradiation With Capecitabine and Cetuximab

Completed·AAustrian Breast & Colorectal Cancer Study Group·Phase 2·NCT00297128·31 enrolled

Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)